Among the subtypes of BC, triple-negative breast cancer (TNBC) is featured by the lack of expression of hormone receptor (HR) and human epidermal growth factor receptor-2 (HER2) and is essentially correlated to the relatively impaired survival and also necessitates the employment of other molecular markers for prognostication and treatment response evaluation [2]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.